Why Institutions Do not Participate in Ovarian Cancer Trials - Results from a Survey in Germany

Onkologie

Volumn 28, Issue 1, 2005, Pages

  Sehouli, Jalid ^a   Kostromitskaia, Julia ^a   Stengel, Dirk ^b   Bois, Andreas Du ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Unfallkrankenhaus Berlin   (Germany)

^c DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

Clinical trial; Ovarian cancer; Participation; Quality assurance

Indexed keywords

CANCER CENTER; CANCER RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; GERMANY; GYNECOLOGY; HEALTH SURVEY; HOSPITAL BED; HUMAN; OVARY CARCINOMA; QUESTIONNAIRE; REVIEW; STATISTICAL ANALYSIS; ARTICLE; EPIDEMIOLOGY; FEMALE; HEALTH CARE QUALITY; HEALTH PERSONNEL ATTITUDE; METHODOLOGY; OVARY TUMOR; REFUSAL TO PARTICIPATE; STATISTICS;

ATTITUDE OF HEALTH PERSONNEL; CLINICAL TRIALS; FEMALE; GERMANY; GYNECOLOGY; HEALTH CARE SURVEYS; HUMANS; ONCOLOGY SERVICE, HOSPITAL; OVARIAN NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; REFUSAL TO PARTICIPATE;

EID: 12544249497     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082183     Document Type: Review

References (24)

1. Stiller CA: Centralised treatment, entry to trials and survival. Br J Cancer 1994;70:352-362.
2. Braunholtz DA, Edwards SJL, Lilford RJ: Are randomized clinical trials good for us (in short term)? Evidence for a 'trial effect'. J Clin Epidemiol 2001;54:217-224.
3. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, Hortobagyi GN: Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicincontaining chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997;15:3171-3177.
4. Peppercorn JM, Weeks JC, Cook EF, Joffe S: Comparison of outcomes in cancer patients treated within and outside clinical trials: Conceptual framework and structured review. Lancet 2004;363:263-270.
5. Ward LC, Fielding JW, Dunn JA, Kelly KA: The selection of cases for randomised trials: A registry survey of concurrent trial and non-trial patients. Br J Cancer 1992;66:943-930.
6. du Bois A, Pfisterer J, Kellermann L, Kreienberg R: Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland: Welchen Einfluß hat die Teilnahme an klinischen Studien? Geburtsh Frauenheilkd 2001;61:863-871.
7. Winger MJ, Macdonald DR, Schold C, Cairncross JG: Selection bias in clinical trials of anaplastic glioma. Ann Neurol 1989;26:531-534.
8. Antman K, Amato D, Wood W, Carson J, Suit H, Proppe K, Carey R, Greenberger J, Wilson R, Frei E 3rd.: Selection bias in clincal trials. J Clin Oncol 1985;3:1142-1147.
9. Hjorth M, Holmberg E, Rödjer S, Westin J: Impact of active and passive exclusions on the results of a clinical trial in multiple myeloma. Br J Haematol 1992;80:55-61.
10. Cottin V, Arpin D, Lasset C, Cordier JF, Brune J, Chauvin F, Trillet-Lenoir V: Small-cell lung cancer: Patients included in clinical trials are not representative of the patient population as a whole. Ann Oncol 1999;10:809-815.
11. Gnant M on behalf of the Austrian Breast and Colorectal Cancer Study Group: Impact of participation in randomized clinical trials on survival of women with early stage breast cancer. Proc Am Soc Clin Oncol 2000;19:74a.
12. Harter P, Schade-Brittinger C, Belau AK, Sehouli J, Loibl S, Lueck HJ, Jackisch C, Canzler U, Kimmig R: AGO-OVAR 14: A retrospective study evaluating the reasons for non-participating in trials in patients with ovarian cancer (OC) treated in coordinating centres of the AGO Studiengruppe Ovarialkarzinom. Proc Am Soc Clin Oncol 2004;23:5081a.
13. Karjalainen S, Palva I: Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. BMJ 1989;299:1069-1989.
14. Burgers JA, Arance A, Ashcroft L, Hodgetts J, Lomax L, Thatcher N: Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer: Response and survival results. Br J Cancer 2002;87:562-566.
15. Owens NJ, Larat EP, Fretwell MD: Improving compliance in the older patient; in Cramer JA, Spilker B (eds): Compliance in Medical Practice and Clinical Trials. New York, NY, Raven, 1991;323-333.
16. Katsares I, Sehouli J, Könsgen D, Mustea A, Oskay G, Lichtenegger W: Subjektive Krankheitstheorien bei Patientinnen mit Ovarialkarzinom - Ergebnisse einer Patientinnenbefragung. Zentralbl Gynakol 2004;V9:45.
17. Clopper C, Pearson K: The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-413.
18. Überla K: Faktorenanalyse. Heidelberg, Springer, 1977, pp 1-22.
19. Berrino F: The EUROCARE Study: Strengths, limitations and perspectives of population-based, comparative studies. Ann Oncol 2003;14(Suppl 5):V9-V13.
20. Emanuel EJ, Schnipper LE, Kamin DY, Levinson J, Lichter AS: The costs of conducting clinical research. J Clin Oncol. 2003;21:4145-4150.
21. Crohns C, Kahlert S, Untch M, Kreienberg R, Jänicke F, Hepp H: Adjuvante Therapie des Mammakarzinoms in Deutschland - Ergebnisse einer Umfrage an 349 gynäkologischen Abteilungen. Geburtsh Frauenheilkd 2000;P2.07.32.
22. Paepke S, Schmieta D, Hüttner C, Hauschild M, Müller S, Sehouli J, Blohmer JU, Lichtenegger W: Therapie von Frauen mit gynäkologischen Krebserkrankungen unter Studienbedingungen - eine Untersuchung zu motivationspsychologischen Aspekten der Studienteilnahme, Compliance und Lebensqualität. Arch Gynecol Obstet 2002;267 (Suppl 1): Abstr PB 03.03:58.
23. Sehouli J, Kostromitskaia J, Stengel D, du Bois A: The physician's view of reasons of non-participating in clinical trials of ovarian cancer - Results of a prospective AGO-NOGGO-study in Germany 2003. J Cancer Res Clin Oncol 2004;130:PO594:127.
24. Sehouli J, Katsares I, Könsgen D, Oskay G, Lichtenegger W: Umgang mit onkologischen Studien im klinischen Alltag. Ein Handbuch für Ärzte. Hamburg, Akademos, 2002.